مقایسه اثربخشی درمان مبتنی بر پذیرش و تعهد به شیوه گروهی و واقعیت درمانی به شیوه گروهی بر سلامت عمومی زنان مبتلا به مولتیپل اسکلروزیس
محورهای موضوعی : سلامت زنانمریم باقری 1 , فرح لطفی کاشانی 2 , محمداسماعیل ابراهیمی 3
1 - دانشجوی دکتری، گروه روانشناسی سلامت، واحد رودهن، دانشگاه آزاد اسلامی، رودهن، ایران
2 - (نویسنده مسئول)، دانشیار گروه روانشناسی، دانشکده علوم پزشکی، دانشگاه آزاد اسلامی، تهران، ایران lotfikasani@riau.ac.ir, tell: 02122006660
3 - استادیار، گروه روانشناسی، واحد همدان، دانشگاه آزاد اسلامی، همدان، ایران
کلید واژه: پذیرش و تعهد, واقعیت درمانی, سلامت عمومی, مولتیپل اسکلروزیس,
چکیده مقاله :
مقدمه: مولتیپل اسکلروزیس، یکی از مهم ترین بیماری های سیستم عصبی می‌باشد که شیوع آن در زنان حدود دو تا سه برابر مردان است. علت اصلی این بیماری به طور کامل شناخته نشده است و هیچ درمان قطعی برای آن وجود ندارد. هدف از انجام مطالعه حاضر، مقایسه اثربخشی درمان مبتنی بر پذیرش و تعهد به شیوه گروهی و واقعیت درمانی به شیوه گروهی بر سلامت عمومی زنان مبتلا به مولتیپل اسکلروزیس بود.
روش پژوهش: روش پژوهش به صورت نیمه آزمایشی با طرح پیش آزمون- پس آزمون و پیگیری با گروه کنترل بود. جامعه پژوهش شامل جامعه پژوهش شامل کلیه زنان متأهل مبتلا به مولتیپل اسکلروزیس در شهر همدان در سال 1400 بودند. از این تعداد، 3 گروه 15 نفره با روش نمونه‌گیری در دسترس انتخاب و به صورت تصادفی به گروه‌های آزمایش و گروه کنترل تقسیم شدند و به پرسش‌نامه سلامت عمومی گلدبرگ (1979) در سه نوبت پیش- پسآزمون و پیگیری پاسخ دادند. داده‌ها با نرم‌افزار SPSS و با استفاده از آزمون تحلیل واريانس مختلط و سطح معنی‌دار 05/0< p تجزیه و تحلیل آماری شدند.
یافته ها: نتایج نشان داد، بین نمرات سلامت عمومی در مراحل پيش آزمون با پس آزمون و پيگيري تفاوت معنادار وجود دارد، همچنین تفاوت بین نمرات پس آزمون با پیگیری معنی دار است. مقايسه ميانگين های تعدیل شده نشان داد كه نمرات سلامت عمومی در مرحله پیش آزمون (4/52=M) بیشتر از مرحله پس آزمون (8/46=M) و پيگيري (6/46=M) است.
نتیجه‌گیری: با توجه به نتایج این پژوهش می‌توان گفت، درمان مبتنی بر پذیرش و تعهد و درمان مبتنی بر واقعیت درمانی منجر به سلامت عمومی در زنان میشوند.
Introduction: Multiple sclerosis is one of the most important diseases of the nervous system, the prevalence of which in women is two to three times that of men. The root cause of this disease is not fully known and there is no definitive treatment for it. The purpose of the present study was to compare the effectiveness of group-based acceptance and commitment therapy and group-based reality therapy on the general health of women with multiple sclerosis.
Research method: The research method was semi-experimental with a pre-test-post-test design and follow-up with a control group. The research population consisted of all married women with multiple sclerosis in Hamadan city in 1400. From this number, 3 groups of 15 people were selected by available sampling method and randomly divided into experimental and control groups and answered the Goldberg General Health Questionnaire (1979) in three pre-test, post-test and follow-up sessions. The subjects of the experimental group were treated with the approach of treatment based on acceptance and commitment and reality therapy, during 8 sessions, 1 session of 60 minutes per week, but no training was given to the control group. The data were statistically analyzed with SPSS software and using mixed analysis of variance test and a significant level of p < 0.05.
Findings: The results showed that there is a significant difference between the general health scores in the pre-test, post-test and follow-up stages, and the difference between the post-test and follow-up scores is significant.
1. Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J, Marrie RA, Montalban X, Yong VW, Thompson AJ, Reich DS; International Advisory Committee on Clinical Trials in Multiple Sclerosis. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023 Jan;22 (1):78-88. doi: 10.1016/S1474-4422 (22)00289-7. Epub 2022 Nov 18. PMID: 36410373; PMCID: PMC10463558.
2. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, Wallin M, Helme A, Angood Napier C, Rijke N, Baneke P. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec;26 (14):1816-1821. doi: 10.1177/1352458520970841. Epub 2020 Nov 11. PMID: 33174475; PMCID: PMC7720355.
3. Lamb YN. Ocrelizumab: A Review in Multiple Sclerosis. Drugs. 2022 Feb;82 (3):323-334. doi: 10.1007/s40265-022-01672-9. Epub 2022 Feb 22. PMID: 35192158; PMCID: PMC8862399.
4. Aghili M, Al Rasool T, Asghari A. The Effectiveness of Self-care Therapy on Psychic Restlessness and Tolerance of Emotional Distress in Women with Multiple Sclerosis. Family and Health. 2023; 12 (4): 152-162. https://journal.astara.ir/article_703848.html?lang=en.
5. Mardan J, Hussain MA, Allan M, Grech LB. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. J Manag Care Spec Pharm. 2021 Sep;27 (9):1273-1295. doi: 10.18553/jmcp.2021.27.9.1273. PMID: 34464209; PMCID: PMC10391062.
6. Neter E, Glass-Marmor L, Wolkowitz A, Lavi I, Miller A. Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis. BMC Neurol. 2021 Mar 25;21 (1):136. doi: 10.1186/s12883-021-02149-0. PMID: 33761887; PMCID: PMC7992850.
7. Kołtuniuk A, Pytel A, Krówczyńska D, Chojdak-Łukasiewicz J. The Quality of Life and Medication Adherence in Patients with Multiple Sclerosis-Cross-Sectional Study. Int J Environ Res Public Health. 2022 Nov 5;19 (21):14549. doi: 10.3390/ijerph192114549. PMID: 36361427; PMCID: PMC9656792.
8. Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F, Weinstock-Guttman B. Multiple sclerosis. Lancet. 2024 Jan 13;403 (10422):183-202. doi: 10.1016/S0140-6736 (23)01473-3. Epub 2023 Nov 7. PMID: 37949093.
9. Uhr L, Rice DR, Mateen FJ. Sociodemographic and clinical factors associated with depression, anxiety, and general mental health in people with multiple sclerosis during the COVID-19 pandemic. Mult Scler Relat Disord. 2021 Nov;56:103327. doi: 10.1016/j.msard.2021.103327. Epub 2021 Oct 11. PMID: 34666242; PMCID: PMC8523026.
10. Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018 Jun;15 (6):382-396. doi: 10.1038/s41571-018-0006-2. PMID: 29636538.
11. Gloster AT, Walder N, Levin ME, Twohig MP, Karekla M. The empirical status of acceptance and commitment therapy: A review of meta-analyses. Journal of Contextual Behavioral Science. 2020; 18: 181–192. https://doi.org/10.1016/j.jcbs.2020.09.009.
12. Ruiz FJ, Luciano C, Flórez CL, Suárez-Falcón JC, Cardona-Betancourt V. A Multiple-Baseline Evaluation of Acceptance and Commitment Therapy Focused on Repetitive Negative Thinking for Comorbid Generalized Anxiety Disorder and Depression. Front Psychol. 2020 Mar 13;11:356. doi: 10.3389/fpsyg.2020.00356. Erratum in: Front Psychol. 2023 Aug 02;14:1258820. doi: 10.3389/fpsyg.2023.1258820. PMID: 32231614; PMCID: PMC7082425.
13. Harris R. ACT made simple: An easy-to-read primer on acceptance and commitment therapy (2nd ed.). New Harbinger Publications; 2019. https://psycnet.apa.org/record/2012-17248-000.
14. Bai Z, Luo S, Zhang L, Wu S, Chi I. Acceptance and Commitment Therapy (ACT) to reduce depression: A systematic review and meta-analysis. J Affect Disord. 2020 Jan 1;260:728-737. doi: 10.1016/j.jad.2019.09.040. Epub 2019 Sep 10. PMID: 31563072.
15. Zhang CQ, Leeming E, Smith P, Chung PK, Hagger MS, Hayes SC. Acceptance and Commitment Therapy for Health Behavior Change: A Contextually-Driven Approach. Front Psychol. 2018 Jan 11;8:2350. doi: 10.3389/fpsyg.2017.02350. PMID: 29375451; PMCID: PMC5769281.
16. Wiley E, Khattab S, Tang A. Examining the effect of virtual reality therapy on cognition post-stroke: a systematic review and meta-analysis. Disabil Rehabil Assist Technol. 2022 Jan;17 (1):50-60. doi: 10.1080/17483107.2020.1755376. Epub 2020 May 2. PMID: 32363955.
17. Freeman D, Lambe S, Kabir T, Petit A, Rosebrock L, Yu LM, Dudley R, Chapman K, Morrison A, O'Regan E, Aynsworth C, Jones J, Murphy E, Powling R, Galal U, Grabey J, Rovira A, Martin J, Hollis C, Clark DM, Waite F; gameChange Trial Group. Automated virtual reality therapy to treat agoraphobic avoidance and distress in patients with psychosis (gameChange): a multicentre, parallel-group, single-blind, randomised, controlled trial in England with mediation and moderation analyses. Lancet Psychiatry. 2022 May;9 (5):375-388. doi: 10.1016/S2215-0366 (22)00060-8. Epub 2022 Apr 5. PMID: 35395204; PMCID: PMC9010306.
18. Taubin D, Berger A, Greenwald D, Greenwald H, Burke C, Gongora DS, Wilens T. A systematic review of virtual reality therapies for substance use disorders: Impact on secondary treatment outcomes. Am J Addict. 2023 Jan;32 (1):13-23. doi: 10.1111/ajad.13342. Epub 2022 Sep 20. PMID: 36128667; PMCID: PMC10557052.
19. Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-Hussaniy HA. Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore). 2024 Feb 23;103 (8):e37297. doi: 10.1097/MD.0000000000037297. PMID: 38394496; PMCID: PMC10883637.
20. Dimeff LA, Linehan MM. Dialectical behavior therapy for substance abusers. Addict Sci Clin Pract. 2008 Jun;4 (2):39-47. doi: 10.1151/ascp084239. PMID: 18497717; PMCID: PMC2797106.
21. Hayes SC, Luoma JB, Bond FW, Masuda A, Lillis J. Acceptance and commitment therapy: model, processes and outcomes. Behav Res Ther. 2006;44 (1):1-25. doi: 10.1016/j.brat.2005.06.006. PMID: 16300724.
22. Glasser W, Zunin LM. Reality therapy. Curr Psychiatr Ther. 1972;12:58-61. PMID: 5032914.
23. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med. 1979 Feb;9 (1):139-45. doi: 10.1017/s0033291700021644. PMID: 424481.
24. Palahang H, Nasr M, Brahani M N, . Shahmohammadi D. Epidemiology of Mental Illnesses in Kashan City. IJPCP 1996; 2 (4) :19-27. URL: http://ijpcp.iums.ac.ir/article-1-1745-fa.html
25. Therapy and Acceptance and Commitment Therapy on Personality Type D and Adherence to Treatment in Patients with Coronary Artery Disease. Journal of Clinical Psychology, 2020; 12 (1): 25-36. doi: 10.22075/jcp.2020.12459.1217.
26. Sheydayi Aghdam Sh, Shamseddini lory S, Abassi S, Yosefi S, Abdollahi S, Moradi joo M. The effectiveness of treatment based on acceptance and commitment in reducing distress and inefficient attitudes in patients with MS. Journal of Thought & Behavior in Clinical Psychology. 2014; 9 (34): 57-66. https://sanad.iau.ir/Journal/jtbcp/Article/1118339.
27. Herman J. Adherence revisited: The patient’s choice. Orthopedic Nurcing. 2024; 21 (2): 79- 82.
28. Morrison, A, & Wertheimer A .I. (2014). Complication of quantitive overviews of studies of adherence. Drug J, 38 (2), 197-210. http://dx.doi.org/10.1177/009286150403800213.
29. Zhang T, Li X, Zhou X, Zhan L, Wu F, Huang Z, Sun Y, Feng Y, Du Q. Virtual Reality Therapy for the Management of Chronic Spinal Pain: Systematic Review and Meta-Analysis. JMIR Serious Games. 2024 Feb 12;12:e50089. doi: 10.2196/50089. PMID: 38345832; PMCID: PMC10897798.
30. Landim SF, López R, Caris A, Castro C, Castillo RD, Avello D, Magnani Branco BH, Valdés-Badilla P, Carmine F, Sandoval C, Vásquez E. Effectiveness of Virtual Reality in Occupational Therapy for Post-Stroke Adults: A Systematic Review. J Clin Med. 2024 Aug 7;13 (16):4615. doi: 10.3390/jcm13164615. PMID: 39200757; PMCID: PMC11354851.
31. Alashram AR. Combined robot-assisted therapy virtual reality for upper limb rehabilitation in stroke survivors: a systematic review of randomized controlled trials. Neurol Sci. 2024 Nov;45 (11):5141-5155. doi: 10.1007/s10072-024-07628-z. Epub 2024 Jun 5. PMID: 38837113.
32. Yamout B, Al-Jumah M, Sahraian MA, Almalik Y, Khaburi JA, Shalaby N, Aljarallah S, Bohlega S, Dahdaleh M, Almahdawi A, Khoury SJ, Koussa S, Slassi E, Daoudi S, Aref H, Mrabet S, Zeineddine M, Zakaria M, Inshasi J, Gouider R, Alroughani R. Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines. Mult Scler Relat Disord. 2024 Mar;83:105435. doi: 10.1016/j.msard.2024.105435. Epub 2024 Jan 7. PMID: 38245998.
33. Wang Y, Wang J, Feng J. Multiple sclerosis and pregnancy: Pathogenesis, influencing factors, and treatment options. Autoimmun Rev. 2023 Nov;22 (11):103449. doi: 10.1016/j.autrev.2023.103449. Epub 2023 Sep 21. PMID: 37741528.
34. Selmaj K, Cree BAC, Barnett M, Thompson A, Hartung HP. Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol. 2024 Jan;271 (1):105-115. doi: 10.1007/s00415-023-11969-8. Epub 2023 Oct 18. PMID: 37851189; PMCID: PMC10769939.
35. Castillo Villagrán D, Yeh EA. Pediatric Multiple Sclerosis: Changing the Trajectory of Progression. Curr Neurol Neurosci Rep. 2023 Nov;23 (11):657-669. doi: 10.1007/s11910-023-01300-3. Epub 2023 Oct 4. PMID: 37792206.
36. Tavakoli Saleh SH, Esmail Ebrahimi M. Effectivenes of Acceptance- Commitment Therapy on the Resillience and Psycological Well-being of Female Patients with Multiple Sclerosis in Hamadan, Iran. Avicenna J Clin Med. 2021; 28 (2): 126-133. doi: 10.52547/ ajcm.28.2.126.
